IBMSi012-A

Registration Summary:

A P E C

IBMS-iPSC-043-05

The cell line is not submitted yet.

(only basic data is shown)

General

Cell Line
hPSCreg name	IBMSi012-A
Cite as:	IBMSi012-A (RRID:CVCL_UK20)
Alternative name(s)	IBMS-iPSC-043-05
Cell line type	Human induced pluripotent stem cell (hiPSC)
Similar lines	No similar lines found.
Last update	2nd January 2019
User feedback	Written by on No feedback available yet. Login to share your feedback, experiences or results with the research community.
Provider
Generator	Institute of Biomedical Sciences, Academia Sinica (IBMS)
External Databases
Cellosaurus	CVCL_UK20
Wikidata	Q94313052
General Information
Publications	Cheng YC et al. Reprogramming of a human induced pluripotent stem cell (iPSC) line (IBMSi012-A) from an early-onset Parkinson's disease patient harboring a homozygous p.D331Y mutation in the PLA2G6 gene. Stem cell research. 2019 May;37:101432. Sharma R et al. 3D Bioprinting Pluripotent Stem Cell Derived Neural Tissues Using a Novel Fibrin Bioink Containing Drug Releasing Microspheres. Frontiers in bioengineering and biotechnology. 2020;8:57. Ke M et al. Azoramide protects iPSC-derived dopaminergic neurons with PLA2G6 D331Y mutation through restoring ER function and CREB signaling. Cell death & disease. 2020 Feb 18;11(2):130. Gao L et al. Case Report: A case of PLA2G6 gene-related early-onset Parkinson's disease and review of literature. Frontiers in neuroscience. 2022;16:1064566. Ma J.. PLA2G6 gene related early onset Parkinson syndrome with cerebellar atrophy: 3 cases report. . 2022-11-08. Gupta Mohit et al. Cellular Reprogramming, Transdifferentiation and Alleviation of the Aging Pathology. Research Journal of Biotechnology. 2023-12-28. Liu Jiabin et al. Unveiling the role of iPLA2β in neurodegeneration: From molecular mechanisms to advanced therapies. Pharmacological Research. 2024-04-00.

hIPSC Derivation

General